s-plus, version 7.0 (Insightful Corp)
90
Structured Review
Insightful Corp
s-plus, version 7.0
S Plus, Version 7.0, supplied by Insightful Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s-plus%2C+version+7%2E0/s+plus+software/pmc04641173-93-13-16
Average 90 stars, based on 1 article reviews
S Plus, Version 7.0, supplied by Insightful Corp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/s-plus%2C+version+7%2E0/s+plus+software/pmc04641173-93-13-16
Average 90 stars, based on 1 article reviews
s-plus, version 7.0 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Software:Article Title: Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative Article Snippet: All statistical analyses were conducted by S. Wen and D. Berry (biostatisticians) using SAS 9.1 (SAS Institute) and Article Title: Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience Article Snippet: Statistical analyses were conducted with SAS 9.1 (SAS Institute) and Article Title: Impact of body mass index (BMI) on the efficacy of plerixafor for hematopoietic progenitor cell (HPC) mobilization. Article Snippet: TO THE EDITOR: Plerixafor in combination with a granulocyte colony-stimulating factor (G-CSF) is commonly used to mobilize hematopoietic progenitor cells (HPC) for autologous transplantation.. Effects of body mass index (BMI) on plerixafor mobilization efficacy are controversial with conflicting results from previous studies.. One hundred and fifty-five patients mobilized with G-CSF plus plerixafor were included in our analysis. Article Title: Phase 1 Clinical Trials in 83 Patients With Pancreatic Cancer Article Snippet: Statistical analyses were carried out using SAS 9.1 (SAS Institute, Cary, NC) and Article Title: Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses Article Snippet: All statistical analyses were performed by S. Wen and D. Berry (biostatisticians) using SAS 9.1 (SAS Institute) and Article Title: Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses Article Snippet: All statistical analyses were performed by SW and DB (biostatisticians) using SAS 9.1 (SAS Institute, Cary, NC) and Article Title: Oral Antineoplastic Agents: Assessing the Delay in Care Article Snippet: Statistical analyses were carried out using SAS 9.1 (SAS Institute, Cary, NC) and Article Title: Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer Article Snippet: Statistical analyses were carried out using SAS 9.1 (SAS Institute, Cary, NC) and Clinical Proteomics:Article Title: Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative Article Snippet: All statistical analyses were conducted by S. Wen and D. Berry (biostatisticians) using SAS 9.1 (SAS Institute) and Article Title: Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience Article Snippet: Statistical analyses were conducted with SAS 9.1 (SAS Institute) and Article Title: Impact of body mass index (BMI) on the efficacy of plerixafor for hematopoietic progenitor cell (HPC) mobilization. Article Snippet: TO THE EDITOR: Plerixafor in combination with a granulocyte colony-stimulating factor (G-CSF) is commonly used to mobilize hematopoietic progenitor cells (HPC) for autologous transplantation.. Effects of body mass index (BMI) on plerixafor mobilization efficacy are controversial with conflicting results from previous studies.. One hundred and fifty-five patients mobilized with G-CSF plus plerixafor were included in our analysis. Article Title: Phase 1 Clinical Trials in 83 Patients With Pancreatic Cancer Article Snippet: Statistical analyses were carried out using SAS 9.1 (SAS Institute, Cary, NC) and Article Title: Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses Article Snippet: All statistical analyses were performed by S. Wen and D. Berry (biostatisticians) using SAS 9.1 (SAS Institute) and Article Title: Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses Article Snippet: All statistical analyses were performed by SW and DB (biostatisticians) using SAS 9.1 (SAS Institute, Cary, NC) and Article Title: Oral Antineoplastic Agents: Assessing the Delay in Care Article Snippet: Statistical analyses were carried out using SAS 9.1 (SAS Institute, Cary, NC) and Article Title: Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer Article Snippet: Statistical analyses were carried out using SAS 9.1 (SAS Institute, Cary, NC) and Biomarker Discovery:Article Title: Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative Article Snippet: All statistical analyses were conducted by S. Wen and D. Berry (biostatisticians) using SAS 9.1 (SAS Institute) and Article Title: Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience Article Snippet: Statistical analyses were conducted with SAS 9.1 (SAS Institute) and Article Title: Impact of body mass index (BMI) on the efficacy of plerixafor for hematopoietic progenitor cell (HPC) mobilization. Article Snippet: TO THE EDITOR: Plerixafor in combination with a granulocyte colony-stimulating factor (G-CSF) is commonly used to mobilize hematopoietic progenitor cells (HPC) for autologous transplantation.. Effects of body mass index (BMI) on plerixafor mobilization efficacy are controversial with conflicting results from previous studies.. One hundred and fifty-five patients mobilized with G-CSF plus plerixafor were included in our analysis. Article Title: Phase 1 Clinical Trials in 83 Patients With Pancreatic Cancer Article Snippet: Statistical analyses were carried out using SAS 9.1 (SAS Institute, Cary, NC) and Article Title: Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses Article Snippet: All statistical analyses were performed by S. Wen and D. Berry (biostatisticians) using SAS 9.1 (SAS Institute) and Article Title: Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses Article Snippet: All statistical analyses were performed by SW and DB (biostatisticians) using SAS 9.1 (SAS Institute, Cary, NC) and Article Title: Oral Antineoplastic Agents: Assessing the Delay in Care Article Snippet: Statistical analyses were carried out using SAS 9.1 (SAS Institute, Cary, NC) and Article Title: Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer Article Snippet: Statistical analyses were carried out using SAS 9.1 (SAS Institute, Cary, NC) and |